Invention Grant
- Patent Title: Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents
-
Application No.: US15571763Application Date: 2016-05-05
-
Publication No.: US10857237B2Publication Date: 2020-12-08
- Inventor: Mohammad Tariq Malik , Martin G. O'Toole , Paula J. Bates
- Applicant: University of Louisville Research Foundation, Inc.
- Applicant Address: US KY Louisville
- Assignee: University of Louisville Research Foundation, Inc.
- Current Assignee: University of Louisville Research Foundation, Inc.
- Current Assignee Address: US KY Louisville
- Agency: Evan Law Group LLC
- International Application: PCT/US2016/030985 WO 20160505
- International Announcement: WO2016/179394 WO 20161110
- Main IPC: A61K49/00
- IPC: A61K49/00 ; A61K47/69 ; A61K41/00 ; A61K49/04 ; A61K31/28 ; A61K45/06 ; A61K31/7105 ; A61K49/18 ; A61K9/00 ; A61K47/54 ; A61P35/00 ; C07K16/18 ; C07K16/30 ; C12N15/115
Abstract:
A composition comprises an anti-nucleolin agent conjugated to nanoparticles, and optionally containing gadolinium. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier. The composition enhances the effectiveness of radiation therapy, enhancing contrast in X-ray imaging techniques, and when gadolinium is present, provide cancer selective MRI contrast agents.
Public/Granted literature
- US20180200385A1 ANTI-NUCLEOLIN AGENT-CONJUGATED NANOPARTICLES AS RADIO-SENSITIZERS AND MRI AND/OR X-RAY CONTRAST AGENTS Public/Granted day:2018-07-19
Information query
